Episode 59
Biotech Hangout
00:00
The CEO of T.G. Therapeutics Is Calling Out the BAML Analyst
The analyst's price target, I thought I heard it was like $3 a share. And this is like a $35 stock, so that itself is a pretty unusual setup and you're almost asking for a little bit of trouble when you go in with the price target but it's like 90% below where the stock is trading. You've actually heard very good things from MS specialists, almost surprising, almost a little incongruent to the product's differentiation. In addition to that, we've picked up anecdotally that some MS specialists may have bought shares in TG therapeutic stock, which is entirely legal.
Transcript
Play full episode
